nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—HTR3A—myenteric nerve plexus—systemic scleroderma	0.0482	0.159	CbGeAlD
Loxapine—HTR7—myenteric nerve plexus—systemic scleroderma	0.0312	0.103	CbGeAlD
Loxapine—HTR7—pulmonary artery—systemic scleroderma	0.0221	0.0728	CbGeAlD
Loxapine—HTR2A—myenteric nerve plexus—systemic scleroderma	0.0195	0.0642	CbGeAlD
Loxapine—HTR2A—pulmonary artery—systemic scleroderma	0.0138	0.0454	CbGeAlD
Loxapine—HTR1B—artery—systemic scleroderma	0.0106	0.035	CbGeAlD
Loxapine—HTR1D—artery—systemic scleroderma	0.0103	0.0339	CbGeAlD
Loxapine—HTR1B—blood vessel—systemic scleroderma	0.00827	0.0273	CbGeAlD
Loxapine—HTR7—artery—systemic scleroderma	0.00819	0.027	CbGeAlD
Loxapine—HTR1D—blood vessel—systemic scleroderma	0.00801	0.0264	CbGeAlD
Loxapine—HTR7—endothelium—systemic scleroderma	0.00692	0.0228	CbGeAlD
Loxapine—HTR7—blood vessel—systemic scleroderma	0.00638	0.021	CbGeAlD
Loxapine—HRH2—skin of body—systemic scleroderma	0.00581	0.0192	CbGeAlD
Loxapine—CHRM5—skin of body—systemic scleroderma	0.00555	0.0183	CbGeAlD
Loxapine—HTR2A—artery—systemic scleroderma	0.00511	0.0168	CbGeAlD
Loxapine—HRH2—digestive system—systemic scleroderma	0.00465	0.0153	CbGeAlD
Loxapine—HTR2A—endothelium—systemic scleroderma	0.00431	0.0142	CbGeAlD
Loxapine—HTR1D—connective tissue—systemic scleroderma	0.00411	0.0135	CbGeAlD
Loxapine—ADRB1—connective tissue—systemic scleroderma	0.00399	0.0132	CbGeAlD
Loxapine—HTR2A—blood vessel—systemic scleroderma	0.00398	0.0131	CbGeAlD
Loxapine—HRH2—lung—systemic scleroderma	0.00388	0.0128	CbGeAlD
Loxapine—HTR3A—digestive system—systemic scleroderma	0.00365	0.012	CbGeAlD
Loxapine—HTR7—connective tissue—systemic scleroderma	0.00327	0.0108	CbGeAlD
Loxapine—CHRM3—smooth muscle tissue—systemic scleroderma	0.00314	0.0104	CbGeAlD
Loxapine—HTR3A—lung—systemic scleroderma	0.00305	0.0101	CbGeAlD
Loxapine—HTR7—smooth muscle tissue—systemic scleroderma	0.00299	0.00987	CbGeAlD
Loxapine—SLC6A4—digestive system—systemic scleroderma	0.00278	0.00918	CbGeAlD
Loxapine—SLC6A3—lung—systemic scleroderma	0.00254	0.00837	CbGeAlD
Loxapine—CHRM3—digestive system—systemic scleroderma	0.00248	0.00818	CbGeAlD
Loxapine—HRH1—connective tissue—systemic scleroderma	0.00244	0.00805	CbGeAlD
Loxapine—ADRB1—lung—systemic scleroderma	0.00241	0.00794	CbGeAlD
Loxapine—ADRA2A—connective tissue—systemic scleroderma	0.0024	0.00791	CbGeAlD
Loxapine—HTR7—digestive system—systemic scleroderma	0.00236	0.00779	CbGeAlD
Loxapine—SLC6A4—lung—systemic scleroderma	0.00232	0.00767	CbGeAlD
Loxapine—CHRM1—lung—systemic scleroderma	0.00232	0.00764	CbGeAlD
Loxapine—HTR7—tendon—systemic scleroderma	0.00225	0.00741	CbGeAlD
Loxapine—HRH1—smooth muscle tissue—systemic scleroderma	0.00223	0.00737	CbGeAlD
Loxapine—ADRA2C—tendon—systemic scleroderma	0.00207	0.00681	CbGeAlD
Loxapine—SLC6A2—lung—systemic scleroderma	0.00205	0.00675	CbGeAlD
Loxapine—HTR2A—connective tissue—systemic scleroderma	0.00204	0.00673	CbGeAlD
Loxapine—HTR7—lung—systemic scleroderma	0.00197	0.00651	CbGeAlD
Loxapine—HTR2A—smooth muscle tissue—systemic scleroderma	0.00187	0.00615	CbGeAlD
Loxapine—DRD2—lung—systemic scleroderma	0.00186	0.00615	CbGeAlD
Loxapine—ADRA2C—lung—systemic scleroderma	0.00181	0.00598	CbGeAlD
Loxapine—Vision blurred—Leflunomide—systemic scleroderma	0.0018	0.00263	CcSEcCtD
Loxapine—Jaundice—Mycophenolate mofetil—systemic scleroderma	0.0018	0.00262	CcSEcCtD
Loxapine—Asthenia—Pentoxifylline—systemic scleroderma	0.00179	0.00262	CcSEcCtD
Loxapine—Tension—Mycophenolic acid—systemic scleroderma	0.00179	0.00261	CcSEcCtD
Loxapine—Hypotension—Captopril—systemic scleroderma	0.00177	0.00258	CcSEcCtD
Loxapine—Pruritus—Pentoxifylline—systemic scleroderma	0.00177	0.00258	CcSEcCtD
Loxapine—HRH1—digestive system—systemic scleroderma	0.00176	0.00582	CbGeAlD
Loxapine—Muscle spasms—Mycophenolic acid—systemic scleroderma	0.00176	0.00256	CcSEcCtD
Loxapine—Vision blurred—Mycophenolic acid—systemic scleroderma	0.00172	0.00251	CcSEcCtD
Loxapine—Agranulocytosis—Mycophenolate mofetil—systemic scleroderma	0.00172	0.00251	CcSEcCtD
Loxapine—Insomnia—Captopril—systemic scleroderma	0.00171	0.0025	CcSEcCtD
Loxapine—Angiopathy—Lisinopril—systemic scleroderma	0.00171	0.0025	CcSEcCtD
Loxapine—Leukopenia—Leflunomide—systemic scleroderma	0.00171	0.0025	CcSEcCtD
Loxapine—Tremor—Mycophenolic acid—systemic scleroderma	0.00171	0.0025	CcSEcCtD
Loxapine—Mediastinal disorder—Lisinopril—systemic scleroderma	0.0017	0.00248	CcSEcCtD
Loxapine—Paraesthesia—Captopril—systemic scleroderma	0.0017	0.00248	CcSEcCtD
Loxapine—Dyspnoea—Captopril—systemic scleroderma	0.00169	0.00247	CcSEcCtD
Loxapine—Somnolence—Captopril—systemic scleroderma	0.00168	0.00246	CcSEcCtD
Loxapine—HRH1—tendon—systemic scleroderma	0.00168	0.00554	CbGeAlD
Loxapine—Agitation—Mycophenolic acid—systemic scleroderma	0.00168	0.00245	CcSEcCtD
Loxapine—Gynaecomastia—Methotrexate—systemic scleroderma	0.00167	0.00244	CcSEcCtD
Loxapine—Cough—Leflunomide—systemic scleroderma	0.00167	0.00244	CcSEcCtD
Loxapine—Alopecia—Lisinopril—systemic scleroderma	0.00167	0.00244	CcSEcCtD
Loxapine—Hepatitis—Mycophenolate mofetil—systemic scleroderma	0.00165	0.00241	CcSEcCtD
Loxapine—Dizziness—Pentoxifylline—systemic scleroderma	0.00165	0.00241	CcSEcCtD
Loxapine—Hypertension—Leflunomide—systemic scleroderma	0.00165	0.00241	CcSEcCtD
Loxapine—ADRA2A—tendon—systemic scleroderma	0.00165	0.00544	CbGeAlD
Loxapine—Hypoaesthesia—Mycophenolate mofetil—systemic scleroderma	0.00165	0.0024	CcSEcCtD
Loxapine—Syncope—Mycophenolic acid—systemic scleroderma	0.00164	0.00239	CcSEcCtD
Loxapine—Leukopenia—Mycophenolic acid—systemic scleroderma	0.00163	0.00238	CcSEcCtD
Loxapine—Fatigue—Captopril—systemic scleroderma	0.00163	0.00238	CcSEcCtD
Loxapine—Chest pain—Leflunomide—systemic scleroderma	0.00163	0.00238	CcSEcCtD
Loxapine—Constipation—Captopril—systemic scleroderma	0.00162	0.00236	CcSEcCtD
Loxapine—Thrombocytopenia—Azathioprine—systemic scleroderma	0.00162	0.00236	CcSEcCtD
Loxapine—Tension—Lisinopril—systemic scleroderma	0.00161	0.00235	CcSEcCtD
Loxapine—Dysgeusia—Lisinopril—systemic scleroderma	0.00161	0.00235	CcSEcCtD
Loxapine—Loss of consciousness—Mycophenolic acid—systemic scleroderma	0.0016	0.00234	CcSEcCtD
Loxapine—Dry mouth—Leflunomide—systemic scleroderma	0.00159	0.00232	CcSEcCtD
Loxapine—Cough—Mycophenolic acid—systemic scleroderma	0.00159	0.00232	CcSEcCtD
Loxapine—Vomiting—Pentoxifylline—systemic scleroderma	0.00159	0.00232	CcSEcCtD
Loxapine—Psychotic disorder—Prednisone—systemic scleroderma	0.00158	0.00231	CcSEcCtD
Loxapine—Convulsion—Mycophenolic acid—systemic scleroderma	0.00158	0.00231	CcSEcCtD
Loxapine—Muscle spasms—Lisinopril—systemic scleroderma	0.00158	0.00231	CcSEcCtD
Loxapine—Rash—Pentoxifylline—systemic scleroderma	0.00158	0.0023	CcSEcCtD
Loxapine—Hypertension—Mycophenolic acid—systemic scleroderma	0.00158	0.0023	CcSEcCtD
Loxapine—Dermatitis—Pentoxifylline—systemic scleroderma	0.00158	0.0023	CcSEcCtD
Loxapine—Headache—Pentoxifylline—systemic scleroderma	0.00157	0.00229	CcSEcCtD
Loxapine—Feeling abnormal—Captopril—systemic scleroderma	0.00156	0.00228	CcSEcCtD
Loxapine—Chest pain—Mycophenolic acid—systemic scleroderma	0.00155	0.00227	CcSEcCtD
Loxapine—Vision blurred—Lisinopril—systemic scleroderma	0.00155	0.00226	CcSEcCtD
Loxapine—Asthenia—Mometasone—systemic scleroderma	0.00155	0.00226	CcSEcCtD
Loxapine—Hypotension—Azathioprine—systemic scleroderma	0.00155	0.00225	CcSEcCtD
Loxapine—Photosensitivity—Methotrexate—systemic scleroderma	0.00154	0.00225	CcSEcCtD
Loxapine—Tremor—Lisinopril—systemic scleroderma	0.00154	0.00225	CcSEcCtD
Loxapine—Nervous system disorder—Leflunomide—systemic scleroderma	0.00153	0.00223	CcSEcCtD
Loxapine—Thrombocytopenia—Leflunomide—systemic scleroderma	0.00153	0.00223	CcSEcCtD
Loxapine—Pruritus—Mometasone—systemic scleroderma	0.00153	0.00223	CcSEcCtD
Loxapine—Tachycardia—Leflunomide—systemic scleroderma	0.00152	0.00222	CcSEcCtD
Loxapine—Dry mouth—Mycophenolic acid—systemic scleroderma	0.00152	0.00222	CcSEcCtD
Loxapine—Confusional state—Mycophenolic acid—systemic scleroderma	0.0015	0.00219	CcSEcCtD
Loxapine—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.0015	0.00219	CcSEcCtD
Loxapine—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00149	0.00218	CcSEcCtD
Loxapine—Oedema—Mycophenolic acid—systemic scleroderma	0.00149	0.00217	CcSEcCtD
Loxapine—Nausea—Pentoxifylline—systemic scleroderma	0.00149	0.00217	CcSEcCtD
Loxapine—Syncope—Lisinopril—systemic scleroderma	0.00147	0.00215	CcSEcCtD
Loxapine—HTR2A—digestive system—systemic scleroderma	0.00147	0.00486	CbGeAlD
Loxapine—HRH1—lung—systemic scleroderma	0.00147	0.00486	CbGeAlD
Loxapine—Leukopenia—Lisinopril—systemic scleroderma	0.00147	0.00215	CcSEcCtD
Loxapine—Shock—Mycophenolic acid—systemic scleroderma	0.00147	0.00214	CcSEcCtD
Loxapine—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.00146	0.00213	CcSEcCtD
Loxapine—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00146	0.00213	CcSEcCtD
Loxapine—Hypotension—Leflunomide—systemic scleroderma	0.00146	0.00213	CcSEcCtD
Loxapine—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.00146	0.00213	CcSEcCtD
Loxapine—Tachycardia—Mycophenolic acid—systemic scleroderma	0.00145	0.00212	CcSEcCtD
Loxapine—ADRA2A—lung—systemic scleroderma	0.00145	0.00477	CbGeAlD
Loxapine—Loss of consciousness—Lisinopril—systemic scleroderma	0.00145	0.00211	CcSEcCtD
Loxapine—Cough—Lisinopril—systemic scleroderma	0.00143	0.00209	CcSEcCtD
Loxapine—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00143	0.00208	CcSEcCtD
Loxapine—Tension—Mycophenolate mofetil—systemic scleroderma	0.00141	0.00206	CcSEcCtD
Loxapine—Insomnia—Leflunomide—systemic scleroderma	0.00141	0.00206	CcSEcCtD
Loxapine—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.00141	0.00206	CcSEcCtD
Loxapine—Paraesthesia—Leflunomide—systemic scleroderma	0.0014	0.00205	CcSEcCtD
Loxapine—HTR2A—tendon—systemic scleroderma	0.0014	0.00462	CbGeAlD
Loxapine—Chest pain—Lisinopril—systemic scleroderma	0.0014	0.00204	CcSEcCtD
Loxapine—Dyspnoea—Leflunomide—systemic scleroderma	0.00139	0.00203	CcSEcCtD
Loxapine—Hypotension—Mycophenolic acid—systemic scleroderma	0.00139	0.00203	CcSEcCtD
Loxapine—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.00139	0.00202	CcSEcCtD
Loxapine—Cerebrovascular accident—Methotrexate—systemic scleroderma	0.00138	0.00202	CcSEcCtD
Loxapine—Vomiting—Mometasone—systemic scleroderma	0.00137	0.002	CcSEcCtD
Loxapine—Dry mouth—Lisinopril—systemic scleroderma	0.00137	0.002	CcSEcCtD
Loxapine—Feeling abnormal—Azathioprine—systemic scleroderma	0.00136	0.00199	CcSEcCtD
Loxapine—Rash—Mometasone—systemic scleroderma	0.00136	0.00198	CcSEcCtD
Loxapine—Asthenia—Captopril—systemic scleroderma	0.00136	0.00198	CcSEcCtD
Loxapine—Dermatitis—Mometasone—systemic scleroderma	0.00136	0.00198	CcSEcCtD
Loxapine—Confusional state—Lisinopril—systemic scleroderma	0.00135	0.00197	CcSEcCtD
Loxapine—Headache—Mometasone—systemic scleroderma	0.00135	0.00197	CcSEcCtD
Loxapine—Tremor—Mycophenolate mofetil—systemic scleroderma	0.00135	0.00197	CcSEcCtD
Loxapine—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00135	0.00197	CcSEcCtD
Loxapine—Insomnia—Mycophenolic acid—systemic scleroderma	0.00135	0.00197	CcSEcCtD
Loxapine—Fatigue—Leflunomide—systemic scleroderma	0.00135	0.00196	CcSEcCtD
Loxapine—Oedema—Lisinopril—systemic scleroderma	0.00134	0.00196	CcSEcCtD
Loxapine—Pruritus—Captopril—systemic scleroderma	0.00134	0.00196	CcSEcCtD
Loxapine—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.00134	0.00195	CcSEcCtD
Loxapine—Constipation—Leflunomide—systemic scleroderma	0.00134	0.00195	CcSEcCtD
Loxapine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00133	0.00194	CcSEcCtD
Loxapine—Somnolence—Mycophenolic acid—systemic scleroderma	0.00132	0.00193	CcSEcCtD
Loxapine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.00132	0.00193	CcSEcCtD
Loxapine—Shock—Lisinopril—systemic scleroderma	0.00132	0.00193	CcSEcCtD
Loxapine—Thrombocytopenia—Lisinopril—systemic scleroderma	0.00131	0.00192	CcSEcCtD
Loxapine—Tachycardia—Lisinopril—systemic scleroderma	0.00131	0.00191	CcSEcCtD
Loxapine—Syncope—Mycophenolate mofetil—systemic scleroderma	0.00129	0.00189	CcSEcCtD
Loxapine—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.00129	0.00188	CcSEcCtD
Loxapine—Feeling abnormal—Leflunomide—systemic scleroderma	0.00129	0.00188	CcSEcCtD
Loxapine—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00129	0.00188	CcSEcCtD
Loxapine—Fatigue—Mycophenolic acid—systemic scleroderma	0.00128	0.00187	CcSEcCtD
Loxapine—Nausea—Mometasone—systemic scleroderma	0.00128	0.00187	CcSEcCtD
Loxapine—Weight increased—Prednisone—systemic scleroderma	0.00128	0.00186	CcSEcCtD
Loxapine—Constipation—Mycophenolic acid—systemic scleroderma	0.00127	0.00186	CcSEcCtD
Loxapine—Weight decreased—Prednisone—systemic scleroderma	0.00127	0.00185	CcSEcCtD
Loxapine—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.00127	0.00185	CcSEcCtD
Loxapine—Cough—Mycophenolate mofetil—systemic scleroderma	0.00126	0.00183	CcSEcCtD
Loxapine—Hypotension—Lisinopril—systemic scleroderma	0.00125	0.00183	CcSEcCtD
Loxapine—Dizziness—Captopril—systemic scleroderma	0.00125	0.00183	CcSEcCtD
Loxapine—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.00125	0.00182	CcSEcCtD
Loxapine—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.00124	0.00181	CcSEcCtD
Loxapine—HTR2A—lung—systemic scleroderma	0.00123	0.00406	CbGeAlD
Loxapine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00123	0.00179	CcSEcCtD
Loxapine—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.00123	0.00179	CcSEcCtD
Loxapine—Hypersensitivity—Azathioprine—systemic scleroderma	0.00122	0.00178	CcSEcCtD
Loxapine—Insomnia—Lisinopril—systemic scleroderma	0.00121	0.00177	CcSEcCtD
Loxapine—Paraesthesia—Lisinopril—systemic scleroderma	0.0012	0.00176	CcSEcCtD
Loxapine—Vomiting—Captopril—systemic scleroderma	0.0012	0.00176	CcSEcCtD
Loxapine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.0012	0.00175	CcSEcCtD
Loxapine—Dyspnoea—Lisinopril—systemic scleroderma	0.0012	0.00175	CcSEcCtD
Loxapine—Rash—Captopril—systemic scleroderma	0.00119	0.00174	CcSEcCtD
Loxapine—Dermatitis—Captopril—systemic scleroderma	0.00119	0.00174	CcSEcCtD
Loxapine—Somnolence—Lisinopril—systemic scleroderma	0.00119	0.00174	CcSEcCtD
Loxapine—Headache—Captopril—systemic scleroderma	0.00119	0.00173	CcSEcCtD
Loxapine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.00119	0.00173	CcSEcCtD
Loxapine—Oedema—Mycophenolate mofetil—systemic scleroderma	0.00118	0.00172	CcSEcCtD
Loxapine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00116	0.00169	CcSEcCtD
Loxapine—Fatigue—Lisinopril—systemic scleroderma	0.00116	0.00169	CcSEcCtD
Loxapine—Shock—Mycophenolate mofetil—systemic scleroderma	0.00116	0.00169	CcSEcCtD
Loxapine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00115	0.00168	CcSEcCtD
Loxapine—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.00115	0.00168	CcSEcCtD
Loxapine—Hypersensitivity—Leflunomide—systemic scleroderma	0.00115	0.00168	CcSEcCtD
Loxapine—Constipation—Lisinopril—systemic scleroderma	0.00115	0.00167	CcSEcCtD
Loxapine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.00115	0.00167	CcSEcCtD
Loxapine—Nausea—Captopril—systemic scleroderma	0.00113	0.00164	CcSEcCtD
Loxapine—Asthenia—Leflunomide—systemic scleroderma	0.00112	0.00163	CcSEcCtD
Loxapine—Feeling abnormal—Lisinopril—systemic scleroderma	0.00111	0.00161	CcSEcCtD
Loxapine—Pruritus—Leflunomide—systemic scleroderma	0.0011	0.00161	CcSEcCtD
Loxapine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.0011	0.0016	CcSEcCtD
Loxapine—Dizziness—Azathioprine—systemic scleroderma	0.00109	0.0016	CcSEcCtD
Loxapine—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.00107	0.00156	CcSEcCtD
Loxapine—Asthenia—Mycophenolic acid—systemic scleroderma	0.00107	0.00156	CcSEcCtD
Loxapine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00155	CcSEcCtD
Loxapine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00154	CcSEcCtD
Loxapine—Pruritus—Mycophenolic acid—systemic scleroderma	0.00105	0.00154	CcSEcCtD
Loxapine—Vomiting—Azathioprine—systemic scleroderma	0.00105	0.00153	CcSEcCtD
Loxapine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00105	0.00153	CcSEcCtD
Loxapine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00105	0.00153	CcSEcCtD
Loxapine—Drowsiness—Methotrexate—systemic scleroderma	0.00104	0.00152	CcSEcCtD
Loxapine—Rash—Azathioprine—systemic scleroderma	0.00104	0.00152	CcSEcCtD
Loxapine—Dermatitis—Azathioprine—systemic scleroderma	0.00104	0.00152	CcSEcCtD
Loxapine—Headache—Azathioprine—systemic scleroderma	0.00104	0.00151	CcSEcCtD
Loxapine—Dizziness—Leflunomide—systemic scleroderma	0.00103	0.00151	CcSEcCtD
Loxapine—Renal failure—Methotrexate—systemic scleroderma	0.00103	0.0015	CcSEcCtD
Loxapine—Angiopathy—Prednisone—systemic scleroderma	0.00102	0.00149	CcSEcCtD
Loxapine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00102	0.00148	CcSEcCtD
Loxapine—Constipation—Mycophenolate mofetil—systemic scleroderma	0.00101	0.00147	CcSEcCtD
Loxapine—Vomiting—Leflunomide—systemic scleroderma	0.000993	0.00145	CcSEcCtD
Loxapine—Alopecia—Prednisone—systemic scleroderma	0.000991	0.00145	CcSEcCtD
Loxapine—Hypersensitivity—Lisinopril—systemic scleroderma	0.000989	0.00144	CcSEcCtD
Loxapine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000985	0.00144	CcSEcCtD
Loxapine—Rash—Leflunomide—systemic scleroderma	0.000985	0.00144	CcSEcCtD
Loxapine—Dermatitis—Leflunomide—systemic scleroderma	0.000984	0.00144	CcSEcCtD
Loxapine—Nausea—Azathioprine—systemic scleroderma	0.000982	0.00143	CcSEcCtD
Loxapine—Headache—Leflunomide—systemic scleroderma	0.000978	0.00143	CcSEcCtD
Loxapine—Agranulocytosis—Methotrexate—systemic scleroderma	0.000975	0.00142	CcSEcCtD
Loxapine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000969	0.00141	CcSEcCtD
Loxapine—Asthenia—Lisinopril—systemic scleroderma	0.000963	0.0014	CcSEcCtD
Loxapine—Pruritus—Lisinopril—systemic scleroderma	0.000949	0.00139	CcSEcCtD
Loxapine—Vomiting—Mycophenolic acid—systemic scleroderma	0.000947	0.00138	CcSEcCtD
Loxapine—Rash—Mycophenolic acid—systemic scleroderma	0.000939	0.00137	CcSEcCtD
Loxapine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000938	0.00137	CcSEcCtD
Loxapine—Hepatitis—Methotrexate—systemic scleroderma	0.000938	0.00137	CcSEcCtD
Loxapine—Headache—Mycophenolic acid—systemic scleroderma	0.000933	0.00136	CcSEcCtD
Loxapine—Nausea—Leflunomide—systemic scleroderma	0.000928	0.00135	CcSEcCtD
Loxapine—Vision blurred—Prednisone—systemic scleroderma	0.00092	0.00134	CcSEcCtD
Loxapine—Agitation—Prednisone—systemic scleroderma	0.000897	0.00131	CcSEcCtD
Loxapine—Dizziness—Lisinopril—systemic scleroderma	0.000887	0.00129	CcSEcCtD
Loxapine—Nausea—Mycophenolic acid—systemic scleroderma	0.000885	0.00129	CcSEcCtD
Loxapine—Syncope—Prednisone—systemic scleroderma	0.000876	0.00128	CcSEcCtD
Loxapine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000866	0.00126	CcSEcCtD
Loxapine—Loss of consciousness—Prednisone—systemic scleroderma	0.000858	0.00125	CcSEcCtD
Loxapine—Vomiting—Lisinopril—systemic scleroderma	0.000853	0.00124	CcSEcCtD
Loxapine—Angiopathy—Methotrexate—systemic scleroderma	0.000851	0.00124	CcSEcCtD
Loxapine—Rash—Lisinopril—systemic scleroderma	0.000846	0.00123	CcSEcCtD
Loxapine—Convulsion—Prednisone—systemic scleroderma	0.000846	0.00123	CcSEcCtD
Loxapine—Dermatitis—Lisinopril—systemic scleroderma	0.000845	0.00123	CcSEcCtD
Loxapine—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000845	0.00123	CcSEcCtD
Loxapine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000844	0.00123	CcSEcCtD
Loxapine—Hypertension—Prednisone—systemic scleroderma	0.000843	0.00123	CcSEcCtD
Loxapine—Headache—Lisinopril—systemic scleroderma	0.000841	0.00123	CcSEcCtD
Loxapine—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000832	0.00121	CcSEcCtD
Loxapine—Alopecia—Methotrexate—systemic scleroderma	0.000828	0.00121	CcSEcCtD
Loxapine—Dysgeusia—Methotrexate—systemic scleroderma	0.000799	0.00117	CcSEcCtD
Loxapine—Nausea—Lisinopril—systemic scleroderma	0.000797	0.00116	CcSEcCtD
Loxapine—Oedema—Prednisone—systemic scleroderma	0.000797	0.00116	CcSEcCtD
Loxapine—Shock—Prednisone—systemic scleroderma	0.000784	0.00114	CcSEcCtD
Loxapine—Nervous system disorder—Prednisone—systemic scleroderma	0.000782	0.00114	CcSEcCtD
Loxapine—Tachycardia—Prednisone—systemic scleroderma	0.000778	0.00113	CcSEcCtD
Loxapine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000777	0.00113	CcSEcCtD
Loxapine—Vision blurred—Methotrexate—systemic scleroderma	0.000769	0.00112	CcSEcCtD
Loxapine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000748	0.00109	CcSEcCtD
Loxapine—Rash—Mycophenolate mofetil—systemic scleroderma	0.000741	0.00108	CcSEcCtD
Loxapine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000741	0.00108	CcSEcCtD
Loxapine—Headache—Mycophenolate mofetil—systemic scleroderma	0.000737	0.00107	CcSEcCtD
Loxapine—Leukopenia—Methotrexate—systemic scleroderma	0.000731	0.00107	CcSEcCtD
Loxapine—Insomnia—Prednisone—systemic scleroderma	0.000721	0.00105	CcSEcCtD
Loxapine—Paraesthesia—Prednisone—systemic scleroderma	0.000716	0.00104	CcSEcCtD
Loxapine—Cough—Methotrexate—systemic scleroderma	0.000712	0.00104	CcSEcCtD
Loxapine—Convulsion—Methotrexate—systemic scleroderma	0.000707	0.00103	CcSEcCtD
Loxapine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000698	0.00102	CcSEcCtD
Loxapine—Chest pain—Methotrexate—systemic scleroderma	0.000695	0.00101	CcSEcCtD
Loxapine—Fatigue—Prednisone—systemic scleroderma	0.000687	0.001	CcSEcCtD
Loxapine—Constipation—Prednisone—systemic scleroderma	0.000682	0.000994	CcSEcCtD
Loxapine—Confusional state—Methotrexate—systemic scleroderma	0.000672	0.00098	CcSEcCtD
Loxapine—Feeling abnormal—Prednisone—systemic scleroderma	0.000657	0.000958	CcSEcCtD
Loxapine—Nervous system disorder—Methotrexate—systemic scleroderma	0.000653	0.000953	CcSEcCtD
Loxapine—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000652	0.000952	CcSEcCtD
Loxapine—Hypotension—Methotrexate—systemic scleroderma	0.000622	0.000908	CcSEcCtD
Loxapine—Insomnia—Methotrexate—systemic scleroderma	0.000602	0.000879	CcSEcCtD
Loxapine—Paraesthesia—Methotrexate—systemic scleroderma	0.000598	0.000873	CcSEcCtD
Loxapine—Dyspnoea—Methotrexate—systemic scleroderma	0.000594	0.000866	CcSEcCtD
Loxapine—Somnolence—Methotrexate—systemic scleroderma	0.000592	0.000864	CcSEcCtD
Loxapine—Hypersensitivity—Prednisone—systemic scleroderma	0.000587	0.000857	CcSEcCtD
Loxapine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000575	0.000839	CcSEcCtD
Loxapine—Fatigue—Methotrexate—systemic scleroderma	0.000574	0.000838	CcSEcCtD
Loxapine—Asthenia—Prednisone—systemic scleroderma	0.000572	0.000834	CcSEcCtD
Loxapine—Pruritus—Prednisone—systemic scleroderma	0.000564	0.000823	CcSEcCtD
Loxapine—Feeling abnormal—Methotrexate—systemic scleroderma	0.000549	0.000801	CcSEcCtD
Loxapine—Dizziness—Prednisone—systemic scleroderma	0.000527	0.000769	CcSEcCtD
Loxapine—Vomiting—Prednisone—systemic scleroderma	0.000507	0.000739	CcSEcCtD
Loxapine—Rash—Prednisone—systemic scleroderma	0.000503	0.000733	CcSEcCtD
Loxapine—Dermatitis—Prednisone—systemic scleroderma	0.000502	0.000733	CcSEcCtD
Loxapine—Headache—Prednisone—systemic scleroderma	0.000499	0.000729	CcSEcCtD
Loxapine—Hypersensitivity—Methotrexate—systemic scleroderma	0.000491	0.000716	CcSEcCtD
Loxapine—Asthenia—Methotrexate—systemic scleroderma	0.000478	0.000697	CcSEcCtD
Loxapine—Nausea—Prednisone—systemic scleroderma	0.000473	0.000691	CcSEcCtD
Loxapine—Pruritus—Methotrexate—systemic scleroderma	0.000471	0.000688	CcSEcCtD
Loxapine—Dizziness—Methotrexate—systemic scleroderma	0.00044	0.000643	CcSEcCtD
Loxapine—Vomiting—Methotrexate—systemic scleroderma	0.000423	0.000618	CcSEcCtD
Loxapine—Rash—Methotrexate—systemic scleroderma	0.00042	0.000613	CcSEcCtD
Loxapine—Dermatitis—Methotrexate—systemic scleroderma	0.00042	0.000612	CcSEcCtD
Loxapine—Headache—Methotrexate—systemic scleroderma	0.000417	0.000609	CcSEcCtD
Loxapine—Nausea—Methotrexate—systemic scleroderma	0.000396	0.000577	CcSEcCtD
Loxapine—HTR1A—Signaling Pathways—RHOB—systemic scleroderma	9.43e-06	0.00082	CbGpPWpGaD
Loxapine—ADRB1—GPCR downstream signaling—EDN1—systemic scleroderma	9.38e-06	0.000816	CbGpPWpGaD
Loxapine—ADRA2A—Hemostasis—MMP1—systemic scleroderma	9.38e-06	0.000816	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—RHOB—systemic scleroderma	9.38e-06	0.000816	CbGpPWpGaD
Loxapine—HTR2A—GPCR ligand binding—CCL2—systemic scleroderma	9.38e-06	0.000816	CbGpPWpGaD
Loxapine—HRH1—GPCR ligand binding—CCL2—systemic scleroderma	9.36e-06	0.000814	CbGpPWpGaD
Loxapine—DRD3—Signaling by GPCR—EDN1—systemic scleroderma	9.35e-06	0.000813	CbGpPWpGaD
Loxapine—CHRM1—GPCR ligand binding—CCL2—systemic scleroderma	9.33e-06	0.000811	CbGpPWpGaD
Loxapine—CHRM3—GPCR ligand binding—CCL2—systemic scleroderma	9.3e-06	0.000809	CbGpPWpGaD
Loxapine—ADRA2B—GPCR downstream signaling—EDN1—systemic scleroderma	9.3e-06	0.000809	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—HSPG2—systemic scleroderma	9.3e-06	0.000809	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—HSPG2—systemic scleroderma	9.21e-06	0.000801	CbGpPWpGaD
Loxapine—CHRM2—GPCR ligand binding—CCL2—systemic scleroderma	9.21e-06	0.000801	CbGpPWpGaD
Loxapine—ADRA1A—GPCR ligand binding—CCL2—systemic scleroderma	9.18e-06	0.000799	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—RHOB—systemic scleroderma	9.13e-06	0.000794	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—HSPG2—systemic scleroderma	9.11e-06	0.000792	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—RHOB—systemic scleroderma	8.98e-06	0.000781	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—CSK—systemic scleroderma	8.98e-06	0.000781	CbGpPWpGaD
Loxapine—HTR1A—GPCR downstream signaling—EDN1—systemic scleroderma	8.98e-06	0.000781	CbGpPWpGaD
Loxapine—ADRA2B—Hemostasis—NOS3—systemic scleroderma	8.96e-06	0.00078	CbGpPWpGaD
Loxapine—HTR2C—GPCR downstream signaling—EDN1—systemic scleroderma	8.93e-06	0.000777	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—CSK—systemic scleroderma	8.9e-06	0.000774	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—HSPG2—systemic scleroderma	8.89e-06	0.000773	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—HSPG2—systemic scleroderma	8.85e-06	0.000769	CbGpPWpGaD
Loxapine—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	8.73e-06	0.000759	CbGpPWpGaD
Loxapine—ADRA2C—GPCR downstream signaling—EDN1—systemic scleroderma	8.69e-06	0.000755	CbGpPWpGaD
Loxapine—HTR5A—Signaling Pathways—MMP9—systemic scleroderma	8.62e-06	0.00075	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—HSPG2—systemic scleroderma	8.61e-06	0.000748	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CSK—systemic scleroderma	8.59e-06	0.000747	CbGpPWpGaD
Loxapine—ADRA1B—GPCR downstream signaling—EDN1—systemic scleroderma	8.55e-06	0.000743	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CSK—systemic scleroderma	8.55e-06	0.000743	CbGpPWpGaD
Loxapine—ADRA2A—GPCR ligand binding—CCL2—systemic scleroderma	8.53e-06	0.000742	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—EDN1—systemic scleroderma	8.52e-06	0.000741	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—EDN1—systemic scleroderma	8.48e-06	0.000738	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—HSPG2—systemic scleroderma	8.47e-06	0.000737	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—EDN1—systemic scleroderma	8.44e-06	0.000734	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—EDN1—systemic scleroderma	8.43e-06	0.000733	CbGpPWpGaD
Loxapine—ADRA2C—Hemostasis—NOS3—systemic scleroderma	8.37e-06	0.000728	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—HSPG2—systemic scleroderma	8.36e-06	0.000727	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CSK—systemic scleroderma	8.31e-06	0.000723	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—RHOB—systemic scleroderma	8.28e-06	0.00072	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CSK—systemic scleroderma	8.18e-06	0.000711	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—EDN1—systemic scleroderma	8.15e-06	0.000709	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—RHOB—systemic scleroderma	8.15e-06	0.000709	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—RHOB—systemic scleroderma	8.13e-06	0.000707	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—EDN1—systemic scleroderma	8.11e-06	0.000705	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—RHOB—systemic scleroderma	8.1e-06	0.000705	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—RHOB—systemic scleroderma	8.08e-06	0.000703	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—RHOB—systemic scleroderma	8e-06	0.000696	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—RHOB—systemic scleroderma	7.98e-06	0.000694	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—EDN1—systemic scleroderma	7.89e-06	0.000686	CbGpPWpGaD
Loxapine—DRD2—GPCR downstream signaling—EDN1—systemic scleroderma	7.88e-06	0.000685	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—HSPG2—systemic scleroderma	7.81e-06	0.000679	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—CTGF—systemic scleroderma	7.8e-06	0.000678	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—EDN1—systemic scleroderma	7.76e-06	0.000675	CbGpPWpGaD
Loxapine—HTR2A—GPCR downstream signaling—EDN1—systemic scleroderma	7.75e-06	0.000674	CbGpPWpGaD
Loxapine—HRH1—GPCR downstream signaling—EDN1—systemic scleroderma	7.74e-06	0.000673	CbGpPWpGaD
Loxapine—CHRM1—GPCR downstream signaling—EDN1—systemic scleroderma	7.71e-06	0.000671	CbGpPWpGaD
Loxapine—CHRM3—GPCR downstream signaling—EDN1—systemic scleroderma	7.69e-06	0.000669	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—HSPG2—systemic scleroderma	7.68e-06	0.000668	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—HSPG2—systemic scleroderma	7.67e-06	0.000667	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—HSPG2—systemic scleroderma	7.64e-06	0.000665	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—HSPG2—systemic scleroderma	7.62e-06	0.000662	CbGpPWpGaD
Loxapine—CHRM2—GPCR downstream signaling—EDN1—systemic scleroderma	7.61e-06	0.000662	CbGpPWpGaD
Loxapine—ADRA1A—GPCR downstream signaling—EDN1—systemic scleroderma	7.59e-06	0.00066	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—HSPG2—systemic scleroderma	7.54e-06	0.000656	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CSK—systemic scleroderma	7.54e-06	0.000656	CbGpPWpGaD
Loxapine—HTR6—Signaling by GPCR—CCL2—systemic scleroderma	7.53e-06	0.000655	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—HSPG2—systemic scleroderma	7.52e-06	0.000654	CbGpPWpGaD
Loxapine—HTR7—Signaling by GPCR—CCL2—systemic scleroderma	7.52e-06	0.000654	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—CCL2—systemic scleroderma	7.48e-06	0.00065	CbGpPWpGaD
Loxapine—HTR1D—Signaling by GPCR—CCL2—systemic scleroderma	7.47e-06	0.00065	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CSK—systemic scleroderma	7.42e-06	0.000645	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—RHOB—systemic scleroderma	7.41e-06	0.000645	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CSK—systemic scleroderma	7.4e-06	0.000644	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CSK—systemic scleroderma	7.38e-06	0.000642	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CSK—systemic scleroderma	7.36e-06	0.00064	CbGpPWpGaD
Loxapine—HTR1B—Signaling by GPCR—CCL2—systemic scleroderma	7.31e-06	0.000636	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CSK—systemic scleroderma	7.29e-06	0.000634	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CSK—systemic scleroderma	7.27e-06	0.000632	CbGpPWpGaD
Loxapine—DRD4—Signaling by GPCR—CCL2—systemic scleroderma	7.2e-06	0.000626	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—EDN1—systemic scleroderma	7.16e-06	0.000622	CbGpPWpGaD
Loxapine—HTR5A—Signaling Pathways—TGFB1—systemic scleroderma	7.1e-06	0.000618	CbGpPWpGaD
Loxapine—CHRM4—Signaling by GPCR—CCL2—systemic scleroderma	7.1e-06	0.000618	CbGpPWpGaD
Loxapine—ADRA2A—GPCR downstream signaling—EDN1—systemic scleroderma	7.05e-06	0.000614	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—EDN1—systemic scleroderma	7.04e-06	0.000612	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—EDN1—systemic scleroderma	7.03e-06	0.000611	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—EDN1—systemic scleroderma	7e-06	0.000609	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—HSPG2—systemic scleroderma	6.99e-06	0.000608	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—EDN1—systemic scleroderma	6.98e-06	0.000607	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—EDN1—systemic scleroderma	6.91e-06	0.000601	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—CTGF—systemic scleroderma	6.9e-06	0.0006	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—EDN1—systemic scleroderma	6.9e-06	0.0006	CbGpPWpGaD
Loxapine—ADRA2A—Hemostasis—NOS3—systemic scleroderma	6.8e-06	0.000592	CbGpPWpGaD
Loxapine—CHRM5—Signaling by GPCR—CCL2—systemic scleroderma	6.8e-06	0.000591	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CSK—systemic scleroderma	6.75e-06	0.000587	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—NOS3—systemic scleroderma	6.66e-06	0.00058	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—CCL2—systemic scleroderma	6.51e-06	0.000566	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—EDN1—systemic scleroderma	6.5e-06	0.000566	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—EDN1—systemic scleroderma	6.5e-06	0.000565	CbGpPWpGaD
Loxapine—DRD1—Signaling by GPCR—CCL2—systemic scleroderma	6.48e-06	0.000564	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—EDN1—systemic scleroderma	6.46e-06	0.000561	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—EDN1—systemic scleroderma	6.41e-06	0.000557	CbGpPWpGaD
Loxapine—DRD3—Signaling by GPCR—CCL2—systemic scleroderma	6.39e-06	0.000556	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—CTGF—systemic scleroderma	6.34e-06	0.000551	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—EDN1—systemic scleroderma	6.32e-06	0.00055	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—EDN1—systemic scleroderma	6.22e-06	0.000541	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—EDN1—systemic scleroderma	6.14e-06	0.000534	CbGpPWpGaD
Loxapine—ADRA2B—Hemostasis—TGFB1—systemic scleroderma	5.93e-06	0.000516	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—EDN1—systemic scleroderma	5.88e-06	0.000511	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—CCL2—systemic scleroderma	5.83e-06	0.000507	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—NOS3—systemic scleroderma	5.8e-06	0.000505	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—CCL2—systemic scleroderma	5.8e-06	0.000504	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—CCL2—systemic scleroderma	5.77e-06	0.000502	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—CCL2—systemic scleroderma	5.76e-06	0.000501	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—EDN1—systemic scleroderma	5.6e-06	0.000487	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—CCL2—systemic scleroderma	5.57e-06	0.000485	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—CCL2—systemic scleroderma	5.54e-06	0.000482	CbGpPWpGaD
Loxapine—ADRA2C—Hemostasis—TGFB1—systemic scleroderma	5.54e-06	0.000482	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—EDN1—systemic scleroderma	5.52e-06	0.00048	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—CCL2—systemic scleroderma	5.39e-06	0.000469	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—MMP9—systemic scleroderma	5.35e-06	0.000465	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—CCL2—systemic scleroderma	5.31e-06	0.000461	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—NOS3—systemic scleroderma	5.17e-06	0.000449	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—NOS3—systemic scleroderma	5.13e-06	0.000447	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—EDN1—systemic scleroderma	5.03e-06	0.000438	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—EDN1—systemic scleroderma	4.99e-06	0.000434	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—CCL2—systemic scleroderma	4.89e-06	0.000425	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—EDN1—systemic scleroderma	4.82e-06	0.000419	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—CCL2—systemic scleroderma	4.81e-06	0.000419	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—CCL2—systemic scleroderma	4.8e-06	0.000418	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—EDN1—systemic scleroderma	4.79e-06	0.000417	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—CCL2—systemic scleroderma	4.79e-06	0.000416	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—CCL2—systemic scleroderma	4.77e-06	0.000415	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—CCL2—systemic scleroderma	4.73e-06	0.000411	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—CCL2—systemic scleroderma	4.71e-06	0.00041	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—EDN1—systemic scleroderma	4.66e-06	0.000405	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—MMP9—systemic scleroderma	4.65e-06	0.000405	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—EDN1—systemic scleroderma	4.59e-06	0.000399	CbGpPWpGaD
Loxapine—ADRA2A—Hemostasis—TGFB1—systemic scleroderma	4.5e-06	0.000391	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—CCL2—systemic scleroderma	4.45e-06	0.000387	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—CCL2—systemic scleroderma	4.44e-06	0.000386	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—CCL2—systemic scleroderma	4.41e-06	0.000384	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—TGFB1—systemic scleroderma	4.41e-06	0.000383	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—CCL2—systemic scleroderma	4.38e-06	0.000381	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—CCL2—systemic scleroderma	4.32e-06	0.000376	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—CCL2—systemic scleroderma	4.25e-06	0.00037	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—EDN1—systemic scleroderma	4.23e-06	0.000368	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—CCL2—systemic scleroderma	4.19e-06	0.000365	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—EDN1—systemic scleroderma	4.16e-06	0.000362	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—EDN1—systemic scleroderma	4.15e-06	0.000361	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—MMP9—systemic scleroderma	4.15e-06	0.000361	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—EDN1—systemic scleroderma	4.14e-06	0.00036	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—EDN1—systemic scleroderma	4.12e-06	0.000359	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—MMP9—systemic scleroderma	4.12e-06	0.000358	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—EDN1—systemic scleroderma	4.08e-06	0.000355	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—EDN1—systemic scleroderma	4.07e-06	0.000354	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—CCL2—systemic scleroderma	4.02e-06	0.000349	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—NOS3—systemic scleroderma	3.96e-06	0.000345	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—NOS3—systemic scleroderma	3.96e-06	0.000344	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—NOS3—systemic scleroderma	3.93e-06	0.000342	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—NOS3—systemic scleroderma	3.85e-06	0.000335	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—TGFB1—systemic scleroderma	3.84e-06	0.000334	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—CCL2—systemic scleroderma	3.83e-06	0.000333	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—NOS3—systemic scleroderma	3.79e-06	0.00033	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—EDN1—systemic scleroderma	3.78e-06	0.000329	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—CCL2—systemic scleroderma	3.78e-06	0.000328	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—NOS3—systemic scleroderma	3.74e-06	0.000325	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—NOS3—systemic scleroderma	3.58e-06	0.000311	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—CCL2—systemic scleroderma	3.44e-06	0.000299	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—TGFB1—systemic scleroderma	3.42e-06	0.000297	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—NOS3—systemic scleroderma	3.41e-06	0.000297	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—CCL2—systemic scleroderma	3.41e-06	0.000297	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—TGFB1—systemic scleroderma	3.4e-06	0.000295	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—NOS3—systemic scleroderma	3.4e-06	0.000295	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—NOS3—systemic scleroderma	3.37e-06	0.000293	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CCL2—systemic scleroderma	3.29e-06	0.000286	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CCL2—systemic scleroderma	3.27e-06	0.000285	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CCL2—systemic scleroderma	3.19e-06	0.000277	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—MMP9—systemic scleroderma	3.18e-06	0.000277	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—MMP9—systemic scleroderma	3.18e-06	0.000276	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—MMP9—systemic scleroderma	3.16e-06	0.000274	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CCL2—systemic scleroderma	3.13e-06	0.000273	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—MMP9—systemic scleroderma	3.09e-06	0.000269	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—NOS3—systemic scleroderma	3.07e-06	0.000267	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—MMP9—systemic scleroderma	3.04e-06	0.000264	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—NOS3—systemic scleroderma	3.04e-06	0.000264	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—NOS3—systemic scleroderma	3.01e-06	0.000261	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—MMP9—systemic scleroderma	3e-06	0.000261	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—NOS3—systemic scleroderma	2.93e-06	0.000255	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—NOS3—systemic scleroderma	2.92e-06	0.000254	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CCL2—systemic scleroderma	2.89e-06	0.000251	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—MMP9—systemic scleroderma	2.87e-06	0.00025	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CCL2—systemic scleroderma	2.84e-06	0.000247	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—NOS3—systemic scleroderma	2.84e-06	0.000247	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CCL2—systemic scleroderma	2.84e-06	0.000247	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CCL2—systemic scleroderma	2.83e-06	0.000246	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CCL2—systemic scleroderma	2.82e-06	0.000245	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—NOS3—systemic scleroderma	2.79e-06	0.000243	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CCL2—systemic scleroderma	2.79e-06	0.000243	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CCL2—systemic scleroderma	2.78e-06	0.000242	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—NOS3—systemic scleroderma	2.76e-06	0.00024	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—MMP9—systemic scleroderma	2.74e-06	0.000238	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—MMP9—systemic scleroderma	2.7e-06	0.000235	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—TGFB1—systemic scleroderma	2.62e-06	0.000228	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—TGFB1—systemic scleroderma	2.62e-06	0.000228	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—TGFB1—systemic scleroderma	2.6e-06	0.000226	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCL2—systemic scleroderma	2.59e-06	0.000225	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—NOS3—systemic scleroderma	2.58e-06	0.000224	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—TGFB1—systemic scleroderma	2.55e-06	0.000221	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—NOS3—systemic scleroderma	2.53e-06	0.00022	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—NOS3—systemic scleroderma	2.53e-06	0.00022	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—NOS3—systemic scleroderma	2.52e-06	0.000219	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—NOS3—systemic scleroderma	2.51e-06	0.000219	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—TGFB1—systemic scleroderma	2.51e-06	0.000218	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—NOS3—systemic scleroderma	2.49e-06	0.000216	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—NOS3—systemic scleroderma	2.48e-06	0.000216	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TGFB1—systemic scleroderma	2.47e-06	0.000215	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MMP9—systemic scleroderma	2.46e-06	0.000214	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MMP9—systemic scleroderma	2.44e-06	0.000212	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TGFB1—systemic scleroderma	2.37e-06	0.000206	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MMP9—systemic scleroderma	2.35e-06	0.000205	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MMP9—systemic scleroderma	2.34e-06	0.000204	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—NOS3—systemic scleroderma	2.31e-06	0.000201	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MMP9—systemic scleroderma	2.28e-06	0.000198	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TGFB1—systemic scleroderma	2.26e-06	0.000196	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MMP9—systemic scleroderma	2.24e-06	0.000195	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TGFB1—systemic scleroderma	2.23e-06	0.000194	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MMP9—systemic scleroderma	2.07e-06	0.00018	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MMP9—systemic scleroderma	2.03e-06	0.000177	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MMP9—systemic scleroderma	2.03e-06	0.000176	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TGFB1—systemic scleroderma	2.03e-06	0.000176	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MMP9—systemic scleroderma	2.02e-06	0.000176	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MMP9—systemic scleroderma	2.02e-06	0.000175	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TGFB1—systemic scleroderma	2.01e-06	0.000175	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MMP9—systemic scleroderma	2e-06	0.000174	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MMP9—systemic scleroderma	1.99e-06	0.000173	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TGFB1—systemic scleroderma	1.94e-06	0.000169	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TGFB1—systemic scleroderma	1.93e-06	0.000168	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TGFB1—systemic scleroderma	1.88e-06	0.000163	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MMP9—systemic scleroderma	1.85e-06	0.000161	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TGFB1—systemic scleroderma	1.85e-06	0.000161	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TGFB1—systemic scleroderma	1.7e-06	0.000148	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TGFB1—systemic scleroderma	1.68e-06	0.000146	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TGFB1—systemic scleroderma	1.67e-06	0.000145	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TGFB1—systemic scleroderma	1.67e-06	0.000145	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TGFB1—systemic scleroderma	1.66e-06	0.000145	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TGFB1—systemic scleroderma	1.65e-06	0.000143	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TGFB1—systemic scleroderma	1.64e-06	0.000143	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TGFB1—systemic scleroderma	1.52e-06	0.000133	CbGpPWpGaD
